1. Home
  2. LEN vs RMD Comparison

LEN vs RMD Comparison

Compare LEN & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lennar Corporation

LEN

Lennar Corporation

HOLD

Current Price

$107.25

Market Cap

31.0B

ML Signal

HOLD

Logo ResMed Inc.

RMD

ResMed Inc.

HOLD

Current Price

$245.07

Market Cap

36.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEN
RMD
Founded
1954
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.0B
36.4B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
LEN
RMD
Price
$107.25
$245.07
Analyst Decision
Hold
Buy
Analyst Count
17
13
Target Price
$115.27
$289.09
AVG Volume (30 Days)
8.4M
1.0M
Earning Date
12-16-2025
01-29-2026
Dividend Yield
1.85%
0.98%
EPS Growth
N/A
29.59
EPS
7.98
9.77
Revenue
$34,186,934,000.00
$5,257,400,000.00
Revenue This Year
$3.04
$9.85
Revenue Next Year
$7.68
$7.32
P/E Ratio
$13.53
$25.07
Revenue Growth
N/A
9.36
52 Week Low
$98.42
$199.92
52 Week High
$144.24
$293.81

Technical Indicators

Market Signals
Indicator
LEN
RMD
Relative Strength Index (RSI) 28.77 42.21
Support Level $118.24 $241.66
Resistance Level $121.35 $255.83
Average True Range (ATR) 3.87 5.07
MACD -1.79 -0.45
Stochastic Oscillator 7.08 18.58

Price Performance

Historical Comparison
LEN
RMD

About LEN Lennar Corporation

Lennar is one of the largest public homebuilders in the United States. The company's homebuilding operations target first-time, move-up, active adult, and luxury homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily and single-family for-rent construction and has invested in numerous housing-related technology startups.

About RMD ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Share on Social Networks: